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INTRODUCTION
Chronic kidney disease (CKD) is a 
major cause of morbidity and mortality 
in patients with hypertension, diabetes, 
and cardiovascular disease (CVD), and 
is a significant public health concern.1,2 
Incidence and prevalence have substantially 
increased over the last decade, with a 
global prevalence of around 11%.3 More 
than 1.9 million people in England have 
diagnosed CKD; the total prevalence 
of adult CKD stage 3–5 was previously 
estimated to be 6%, and rises with age.4 
Persistent albuminuria prevalence (with 
normal estimated glomerular filtration rate 
[eGFR]), which is considered to be CKD 
stage 1, has been estimated to be as high as 
10%.5 Prevalence of diagnosed CKD stage 1 
and 2 is estimated at 3.5–12% of adults 
aged ≥35 years.5 In addition, approximately 
1 million people in the UK have, based on 
their eGFR results, CKD stage 3–5 but are 
not coded.6
In UK primary care, the Quality and 
Outcomes Framework (QOF) incentivises 
maintaining a CKD register that now includes 
classification of glomerular filtration rate 
(GFR) categories G3a to G5 (based on 
eGFR), but the blood pressure (BP) targets, 
angiotensin-converting enzyme inhibitor 
(ACEi)/angiotensin receptor blocker (ARB) 
treatment, and albumin creatinine ratio 
(ACR) testing have been removed.7
CVD is the most common cause of 
mortality in later-stage CKD.8,9 Recognised 
risk factors for CKD include age, sex, 
ethnicity, hypertension, diabetes, CVD, 
smoking, and use of non-steroidal anti-
inflammatory drugs (NSAIDs).10 CKD 
guidance includes BP management targets 
and statins for CVD prevention for all 
individuals with CKD stage 3–5.11,12 The 
systolic BP target in CKD is <140 mmHg 
(target range: 120–139 mmHg), and the 
diastolic BP target is <90 mmHg. For 
patients with type 2 diabetes (T2D) and/or 
a urinary ACR of >70 mg/mmol, BP targets 
are <130/80 mmHg.11 A recent meta-
analysis found that GFR decline may be 
slowed with glycaemic and lipid-lowering 
control, but lacked a protective effect of 
antihypertensives; studies were, however, 
underpowered.13
Coding and management of disease
In the UK, GPs are responsible for the 
management of CKD and there are 
QOF financial incentives for coding and 
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Background
Uncoded chronic kidney disease (CKD) is 
associated with poorer quality of care.
Aim
To ascertain the proportion and determinants 
of CKD, which have not been formally recorded 
(Read coded), and identify differences in 
management and quality-of-care measures for 
patients with coded and uncoded CKD.
Design and setting
Cross-sectional survey undertaken in an 
ethnically diverse adult population using primary 
care electronic health records (EHRs) from GP 
clinics in Lambeth, South London, UK.
Method
Multivariable logistic regression analysis 
examined the association of demographic 
factors, selected comorbidities, deprivation, and 
cardiovascular disease risk management in CKD, 
with coding status as outcome.
Results
In total, the survey involved 286 162 adults, of 
whom 9325 (3.3%) were identified with CKD 
stage 3–5 (assigned as CKD based on estimated 
glomerular filtration rate [eGFR] values). Of those 
identified with CKD, 4239 (45.5%) were Read 
coded, and 5086 (54.5%) were uncoded. Of those 
identified with CKD stage 3–5, individuals aged 
≥50 years were more likely to be coded for CKD, 
compared with those aged <50 years. Lower 
levels of coding were independently associated 
with deprivation and black Caribbean, black 
African, South Asian, and non-stated ethnicities, 
compared with white ethnicity. Prescribed statin 
and angiotensin-converting enzyme inhibitor/
angiotensin receptor blocker medications were 
associated with increased odds of coded CKD.
Conclusion
This study found that >50% of CKD was uncoded 
and, for those patients, quality of care was lower 
compared with those with coded CKD. Future 
research and practices should focus on areas 
of greater deprivation and targeted initiatives for 
those aged <50 years and of black African, black 
Caribbean, South Asian, or non-stated ethnic 
groups. Possible areas for improvement include 
diagnostic coding support, automated CKD 
recording, and clinical decision support (based on 
adjusted eGFR results) in the GP clinical records.
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managing conditions in primary care; these 
are updated annually.7 Read codes and 
SNOMED Clinical Terms (CT) are used 
in the recording of clinical information in 
primary care,14 and include:
• diagnostic codes; 
• measurements (such as laboratory test 
results, BP, height, and weight); 
• drug prescriptions; and
• sociodemographic items.
The importance of CKD clinical coding — 
that is, formal diagnosis — in primary care 
was highlighted in the 2017 National Chronic 
Kidney Disease Audit, which recommended 
improved CKD coding.6 Patients who have 
uncoded CKD may have disease that is 
undiagnosed or missed.15 As 78% of those 
with CKD are managed in primary care, 
the audit noted that, without coding, a large 
number of people are at high risk of a lack of 
monitoring and appropriate follow-up, with 
increased risk of poor outcomes.6 However, 
presently ~70% of patients with CKD are 
coded for CKD in primary care in England 
and Wales,16,17 and evidence suggests there 
is a positive relationship between coding 
and patient management.17 Other studies 
in different settings have shown lower levels 
of CKD coding to be associated with poorer 
health outcomes, including hospitalisation 
and lack of BP target achievement,18,19 and 
lower recording rates for hypertension and 
stroke.20 The authors decided to repeat 
the National Chronic Kidney Disease 
Audit (which comprised largely white, 
rural populations) in a multi-ethnic, urban 
setting,21 using more-recent data. 
Objectives
The study aimed to:
• determine proportion of uncoded CKD, 
based on eGFR values alone;
• identify determinants of receiving a coded 
CKD diagnosis; and
• identify differences in management and 
quality-of-care measures for patients 
with coded and uncoded CKD.
METHOD
Study setting and design
The study was undertaken in Lambeth, 
South London, and involved a cross-
sectional survey of people with a Read 
code for CKD and/or reduced eGFR on the 
health record held by their GP. The authors 
determined coding status, risk factors, and 
measures of CKD management.
Data sources
This study utilised a dataset derived from 
general practice electronic health records 
(EHRs) for one inner-London borough, 
Lambeth DataNet (LDN), extracted in 
October 2013. LDN contains patient-level 
clinical data, prescribing data, laboratory 
data, and demographic information 
(including ethnicity, based on categories 
of the UK 2001 census), risk factors, and 
comorbidities. Demographic factors, 
comorbidities, and other quality-of-care 
measures were investigated in a multi-
ethnic population identified as having 
CKD based on their eGFR. The eGFR 
was calculated from laboratory serum 
creatinine values using the modified four-
variable Modification of Diet in Renal 
Disease (MDRD) equation, adjusted for sex 
and ethnic group.
Study population
The study was carried out using anonymised 
data from adult patients (aged ≥18 years) 
registered with 47 of 49 GP practices based 
in Lambeth, South London. 
Identification of CKD coding status
Coded CKD status was determined 
using QOF CKD descriptive codes, plus 
codes for dialysis or renal transplantation 
(Supplementary Table S1), validated with 
biochemical evidence of CKD based on 
the latest two readings for eGFR levels 
<60 ml/ min/1.73 m2 that were taken 
≥3 months apart. Non-coded CKD was 
defined as individuals who fitted the criteria 
for biochemical CKD, but for whom there 
was no corresponding Read code entry. 
Covariates 
The authors examined factors such as age, 
sex, ethnicity, deprivation level (based on 
the Index of Multiple Deprivation 2015), 
and selected comorbidities that were likely 
to affect renal health outcomes, including 
How this fits in 
The coding of chronic kidney disease 
(CKD) is associated with improved quality 
of care and CVD risk management. This 
study identified health inequalities, with 
lower levels of coding in younger age 
groups (individuals aged <50 years); 
areas of greater deprivation; and black 
Caribbean, black African, South Asian, and 
non-stated ethnic groups compared with 
those of white ethnicity; such individuals 
















Analysis of coding status with
demographic, comorbidities, and
quality of care factors 
Figure 1. Chronic kidney disease identification process. 
CKD = chronic kidney disease.
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hypertension, type 2 diabetes (T2DM), 
coronary heart disease (CHD), heart failure, 
and serious mental illness (SMI), using 
QOF registers at the time of the data 
extraction.22 SMI was selected as this is 
common in CKD,23 and studies report an 
association with increased CVD mortality 
and morbidity.24 Other measured factors 
affecting CKD progression and/or health 
outcomes were: systolic and diastolic 
BP control; statin, ACEi/ARB, and NSAID 
prescribed medication; and lifestyle factors, 
such as smoking and obesity. Ethnicity was 
self-reported and aggregated into seven 
categories: white, black African, black 
Caribbean, South Asian, Chinese, other, and 
non-stated. Non-stated was an available 
option for participants and does not include 
participants who did not answer. Systolic 
BP control was defined as <140 mmHg 
and diastolic BP control as <90 mmHg,11 
based on the average of two latest readings. 
Proteinuria measurements (a measure 
of renal damage) were incomplete and, 
therefore, not included.
Outcomes
The authors examined the following 
metrics relevant to quality of care in CKD, 
comprising:
• proportion of uncoded CKD (based on the 
eGFR);
• determinants of receiving a coded CKD 
diagnosis; and
Table 1. Uncoded and coded CKD Read codes among an adult population with biochemical CKD stage 3–5 
(n = 9325), by selected clinical characteristics
  Uncoded CKD Coded CKD
Variable Total, N n %a n %a P-value
CKD stage ≥3 9325 5086 54.5 4239 45.5
Sex
 Female  5312 2858 53.8 2454 46.2
 Male  4013 2228 55.5 1785 44.5 0.10
Age group, years
 <50 1167 956 81.9 211 18.1 <0.001
 50–59 1464 1077 73.6 387 26.4 
 60–69 1574 942 59.8 632 40.2 
 70–79 2502 1130 45.2 1372 54.8 
 80–89 2117 783 37.0 1334  63.0 
 ≥90 501 198 39.5 303 60.5 
Ethnicity
 White 3847 1758 45.7 2089 54.3 <0.001
 Black African 1440 984 68.3 456 31.7
 Black Caribbean 2196 1297 59.1 899 40.9
 South Asian 540 260 48.1 280 51.9
 Chinese 62 30 48.4 32 51.6
 Other ethnicity 171 98 57.3 73 42.7
 Non-stated 206 129 62.6 77 37.4 
 Missing 863 530 61.4 333 38.6
IMD quintile
 1 (least deprived) 2252 1193 53.0 1059 47.0 0.42
 2 2000 1102 55.1 898 44.9
 3 1600 886 55.4 714 44.6
 4 1741 968 55.6 773 44.4
 5 (most deprived) 1726 932 54.0 794 46.0
 Missing 6 5 83.3 1 16.7
Comorbid conditions
 Previous stroke 678 293 43.2 385 56.8 <0.001
 CHD 1389 500 36.0 889 64.0 <0.001
 Hypertension 6318 2873 45.5 3445 54.5 <0.001
 Type 2 diabetes 2537 1079 42.5 1458 57.5 <0.001
 Heart failure 751 243 32.4 508 67.6 <0.001
 Serious mental illness 431 225 52.2 206 47.8 0.32
aPercentages are calculated using the total figure for each variable as denominator, unless otherwise stated. CHD = coronary heart disease. CKD = chronic kidney disease. 
IMD = Index of Multiple Deprivation.
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• differences in management and quality-
of-care measures between coded and 
uncoded CKD, based on CKD guidance 
from the National Institute for Health 
and Care Excellence, demographic 
factors, patient characteristics, and 
comorbidities.
Analysis
A cross-sectional assessment of people 
with biochemical CKD was used to assess 
factors associated with coding status 
in individuals with CKD, using Stata 
(version 15).
Logistic regression analysis was used to 
determine the association of demographic 
factors, selected comorbidities, and CVD 
risk-management measures with CKD 
coding status. Partly adjusted (adjusted 
for age group and sex) and fully adjusted 
(adjusted for age group, sex, and other 
covariates) analyses were conducted. The 
covariates adjusted for included ethnicity 
(white ethnicity as the reference group), 
locally based deprivation quintile, smoking 
status, comorbidities, and quality-of-
care factors (CVD risk management and 




The population comprised 286 162 
adults from 47 out of 49 GP practices in 
Lambeth, South London. Details of patient 
characteristics can be seen in Table 1. 
CKD coding
Of those identified with CKD (n = 9325), 4239 
(45.5%) had a Read-coded CKD diagnosis, 
and 5086 (54.5%) were uncoded (validated 
with ethnicity-corrected eGFR). In total, 
9325 out of 286 162 (3.3%) individuals were 
identified as having CKD based on eGFR 
values (Figure 1). 
Table 1 summarises risk factors in 
9325 patients with CKD, by coding status. 
The proportion of coded CKD was lower 
in younger age groups (aged <50 years). 
Figure 2 shows coding status by 10-year 
age group. CKD coding rose sharply in 
those aged ≥60 years. Coded CKD showed 
some inequalities between ethnic groups, 
for example, 54.3% of all CKD was coded 
in the white ethnicity group, but only 31.7% 
was coded in the black African and 40.9% 
in the black Caribbean groups, respectively. 
Table 2 shows quality-of-care measures, 
including BP control and pharmacotherapy. 
In patients with uncoded CKD, prescribed 
diuretic, ACEi/ARB, and statin medications 
were lower, but prescribed NSAID 
medications were higher than in patients 
with coded CKD. 
CKD burden and determinants of 
receiving a CKD diagnosis
Of the 9325 individuals with CKD, the 
largest proportion was among those of 
black Caribbean and black African ethnicity, 
which remained after data were adjusted for 
age; age-standardised rates were produced 
Figure 3. Prevalence of CKD stage 3–5 (coded and 
uncoded), by ethnic group in all adults (aged ≥18 years) 
in Lambeth DataNet. Age-adjusted data for the 
population, using the mid-2013 England and Wales 
adult population estimate.25
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Figure 2. CKD Stage 3–5 coding status by age group 
for all adults (aged ≥18 years) in Lambeth DataNet. 
Denominator is total for uncoded and coded groups,  
N = 9325.
CKD = chronic kidney disease.
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using the mid-2013 England and Wales 
population estimate (Figures 3 and 4).25
Table 3 shows the partially and fully 
adjusted analyses of those identified with 
CKD stage 3–5 adjusted for age group 
and sex. In the fully adjusted analyses, of 
those identified with CKD stage 3–5, being 
in an older age group was associated 
with increased odds of CKD being coded 
compared with those aged <50 years. Lower 
levels of coding were associated with all 
levels of deprivation compared with the 
quintile of least deprivation, and with black 
African, black Caribbean, South Asian, and 
non-stated ethnicity compared with white 
ethnicity. Some comorbidities, including 
hypertension, heart failure, and SMI, were 
associated with increased odds of CKD being 
recognised and coded (Table 3). 
Management and quality-of-care 
measures 
Quality-of-care factors, including prescribed 
statins (adjusted odds ratio [OR] 1.38, 95% 
confidence interval [CI] = 1.23 to 1.55) and 
ACEi/ARB medications (adjusted OR 2.24, 
95% CI = 1.97 to 2.54) were associated with 
increased odds of CKD coding. CKD coding 
was associated with lower use of prescribed 
NSAIDs (adjusted OR 0.79, 95% CI = 0.71 to 
0.89).
In a separate analysis, target systolic 
BP control was also associated with an 
increased likelihood of being coded for CKD 
(adjusted OR 1.16, 95% CI = 1.04 to 1.30) 
(data not shown). 
BMI was lower (P = 0.03) and proportion of 
current or ex-smokers higher (P = 0.001) in 
those not coded for CKD; however, BMI and 
smoking were not significantly associated 
with likelihood of CKD coding in the fully 
adjusted model (Table 3).
DISCUSSION
Summary
In this study of participants from ethnically 
diverse populations, the authors found that 
54.5% of CKD was uncoded (that is, not 
formally recognised) and, for these patients, 
quality of care was lower. Younger adults 
(aged <50 years) with CKD were found to be 
less likely to be coded and, therefore, could 
be at risk of adverse CVD outcomes.
The age-adjusted burden of CKD showed 
that the largest proportion of cases were in 
black Caribbean and black African ethnic 
groups. It was found that participants of 
black Caribbean, black African, South Asian, 
and non-stated ethnicity were also less 
likely to be coded for CKD compared with 
those of white ethnicity, which may reflect 
physician recording bias. The association 
between uncoded CKD and black African 
and South Asian ethnicity is important, as 
it demonstrates an ethnic health inequality, 
which remained after adjusting for 
deprivation. 
CKD coding was associated with 
comorbidities including hypertension, heart 
failure, and SMI. For those individuals coded 
for CKD, associated quality-of-care factors 
— such as prescribed statin and ACEi/
ARB medications — were more likely. CKD 
coding was found to be associated with 
Table 2. Uncoded and coded CKD Read codes in an adult population 
with biochemical CKD stage 3–5, by selected quality-of-care 
characteristics
 Uncoded CKD Coded CKD 
 (N = 5086) (N = 4239)
Variable n % n % P-value
BP
 Mean systolic BP <140 mmHg 1411 27.7 1720 40.6 0.80
 Missing 2868 56.4 1550 36.6 
 Mean diastolic BP <90 mmHg 2012 39.6 2535 59.8 <0.001
 Missing 2868 56.4 1550 36.6 
BMI
 >25 kg/m2 3262 64.1 2945 69.5 0.03
 Missing 547 10.8 258 6.1 
Comorbidity history
 Current or ex-smoker 702 13.8 458 10.8 <0.001
 Missing 21 0.4 3 0.1 
 Prescribed NSAID 1394  27.4 884 20.9 <0.001
 Prescribed diuretic 1523 29.9 2066 48.7 <0.001
 Prescribed ACEi/ARB 2210 43.5 3183 75.1 <0.001
 Prescribed statin 2157 42.4 2849 67.2 <0.001
ACEi = angiotensin-converting enzyme inhibitor. ARB = angiotensin receptor blocker. BMI = body mass index. 





























Figure 4. Prevalence of CKD stage 3–5 (coded and 
uncoded), by ethnic group in adults aged ≥65 years 
in Lambeth DataNet. Age-adjusted data for the 
population, using the mid-2013 England and Wales 
adult population estimate.25
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lower use of prescribed NSAIDs, possibly 
due to prescriber practice (less likely to 
prescribe NSAIDs because of concerns 
about renal toxicity). 
Strengths and limitations 
This study examined a number of coding 
determinants in a socioeconomically diverse 
adult population, and assessed CKD quality 
of care. A total of 47 of 49 general practices 
in Lambeth, South London, were included 
in this study, with a high representation of 
black and minority ethnic groups (42.9%; 
compared with the rest of England and 
Wales, 14.0%26), who are at increased risk of 
CKD and associated comorbidities.
The observed limitations are those 
often found with observational data and 
include misclassification, missing data, 
and unmeasured confounders, including 
GP practice factors. As >98% of patients 
in England are registered with a GP,27 data 
capture is high. However, the authors were 
unable to ascertain effect and direction 
of bias, because of missing data and the 
introduction of possible bias for BP control 
and BMI for patients with non-coded versus 
coded CKD. 
Other limitations include selection (due to 
comorbidities and QOF coding) and survivor 
bias. In Lambeth, the population is younger 
and has greater levels of deprivation 
compared with the rest of the UK;28 as such, 
the authors would expect there to be higher 
levels of CKD in an older population.
This study reports an uneven prevalence 
of comorbidities (for example, stroke, CHD, 
and heart failure) between those who were 
coded and uncoded for CKD. This may 
be due to undercoding in the non-coded 
CKD population; however, because of QOF 
incentives, diseases such as stroke and 
CHD are likely to be coded, irrespective of 
CKD coding status. 
It is likely that levels of hypertension are 
underdiagnosed, based on QOF disease 
registers,21 and BP recording was lower in 
non-coded CKD. Drug use was based on 
prescribed medications, although data on 
adherence were not available. Finally, long-
term outcomes, such as mortality, were not 
examined as these were beyond the scope 
of this study. 
Comparison with existing literature
The study presented here identified 
lower levels of CKD coding (45.5%) than 
those identified in the National Chronic 
Kidney Disease Audit (70%),17 but levels 
were similar to those of a recent study 
in Oxfordshire, OxRen, which found that 
44.0% of (predominantly white) individuals 
living with CKD are undiagnosed without 
screening.29 This may reflect selection bias 
in participating GPs in the National Chronic 
Kidney Disease Audit, whereas the study 
presented here may be more reflective 
of busy urban practices. In contrast, one 
study has shown a higher prevalence of 
BP recording in black African and black 
Caribbean populations in the same 
Lambeth population.21
Older age (>50 years), male sex, diabetes, 
and hypertension are associated with CKD 
Table 3. Partially and fully adjusted logistic regression analysis of 
the odds of being Read coded for CKD in an adult population with 
biochemical CKD stage 3–5
 Partially adjusteda Fully adjustedb Fully adjustedb 
Variable OR (95% CI) OR (95% CI2) P-value
Age group, years 
 <50 ref ref 
 50–59 1.63 (1.35 to 1.97) 1.26 (1.01 to 1.57) 0.04
 60–69 3.05 (2.55 to 3.65) 1.86 (1.50 to 2.30) <0.001
 70–79 5.52 (4.66 to 6.53) 2.89 (2.36 to 3.56) <0.001
 80–89 7.76 (6.53 to 9.24) 3.88 (3.13 to 4.81) <0.001
 ≥90 7.00 (5.54 to 8.84) 4.06 (3.04 to 5.43) <0.001
Sex 
 Female ref ref
 Male 1.05 (0.96 to 1.14) 0.97 (0.88 to 1.07) 0.54
Ethnicity
 White ref ref 
 Black African 0.66 (0.58 to 0.76) 0.56 (0.48 to 0.66) <0.001
 Black Caribbean 0.71 (0.63 to 0.79) 0.61 (0.54 to 0.70) <0.001
 South Asian 0.99 (0.82 to 1.20) 0.81 (0.66 to 0.99) 0.04
 Chinese 0.97 (0.58 to 1.64) 0.81 (0.46 to 1.42) 0.46
 Other 0.92 (0.66 to 1.29) 0.83 (0.58 to 1.17) 0.29
 Non-stated 0.57 (0.42 to 0.77) 0.58 (0.41 to 0.81) 0.001
IMD quintile
 1 (least deprived) ref ref 
 2 0.88 (0.77 to 1.00) 0.83 (0.72 to 0.97) 0.02
 3 0.80 (0.70 to 0.92) 0.76 (0.65 to 0.89) 0.001
 4 0.78 (0.69 to 0.89) 0.79 (0.67 to 0.92) 0.002
 5 (most deprived) 0.77 (0.68 to 0.89) 0.76 (0.65 to 0.89) 0.001
Comorbidity history
 Hypertension 2.40 (2.17 to 2.65) 1.43 (1.25 to 1.64) <0.001
 Type 2 diabetes 1.59 (1.44 to 1.75) 1.08 (0.96 to 1.22) 0.21
 Stroke 1.22 (1.04 to 1.44) 0.93 (0.77 to 1.12) 0.46
 Serious mental illness 1.05 (0.86 to 1.29) 1.26 (1.00 to 1.64) 0.05
 Heart failure 2.00 (1.70 to 2.36) 1.34 (1.11 to 1.62) <0.001
 CHD 1.67 (1.47 to 1.89) 1.09 (0.94 to 1.26) 0.27
Quality-of-care factor
 Statin prescribed 2.03 (1.85 to 2.23) 1.38 (1.23 to 1.55) <0.001
 ACEi/ARB prescribed 3.16 (2.88 to 3.47) 2.24 (1.97 to 2.54) <0.001
 NSAID prescribed 0.80 (0.72 to 0.89) 0.79 (0.71 to 0.89) <0.001
 BMI >25 kg/m2 1.28 (1.15 to 1.41) 1.07 (0.95 to 1.20) 0.26
 Current smoker 1.00 (0.88 to 1.15) 1.03 (0.88 to 1.21) 0.71
aAdjusted for age and sex. bAdjusted for all covariates in the table. ACEi = angiotensin-converting enzyme inhibitor. 
ARB = angiotensin receptor blocker. BMI = body mass index. BP = blood pressure. CHD = coronary heart disease. 
CKD = chronic kidney disease. IMD = Index of Multiple Deprivation. NSAID = non-steroidal anti-inflammatory drug. 
OR = odds ratio. 
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coding, and CKD coding is associated with 
receiving key primary care interventions 
recommended for CKD, including systolic 
BP control and pharmacotherapy.17 A 
study by Hull et al has shown hypotensive 
medication to be prescribed unequally 
among ethnic groups for any given range of 
BP control.30 In individuals with hypertension 
(both with and without CKD, adjusted by age 
and sex, and clustered by practice), the 
authors found that achieving the target 
BP (<140/90 mmHg) was better in patients 
of South Asian (OR 1.43, 95% CI = 1.28 to 
1.60) ethnic groups and worse in black 
African (OR 0.79, 95% CI = 0.74 to 0.84) 
ethnic groups, compared with patients of 
white ethnicity.30 A systematic review of BP 
management in CKD populations, including 
minority ethnic groups, showed that quality 
improvement interventions can be effective 
at lowering BP and, potentially, at reducing 
CVD risk and slowing progression in CKD;31 
in addition, modest improvements in systolic 
BP control (2.4 mmHg) were achieved 
through an audit education programme.32 
People of minority ethnic groups are over-
represented on renal replacement therapy 
(CKD stage 5);33 this may be because of 
some of the inequalities highlighted here. 
The awareness of CKD coding in SMI is 
important, as this group is at increased risk 
of CVD mortality.24
Implications for practice 
This study has highlighted the importance 
of CKD coding for improved disease 
management, as well as a health inequality. 
Possible areas for improvement include 
diagnostic coding support, automated CKD 
recording, and clinical decision support 
(based on adjusted eGFR results) in the GP 
clinical records.
The authors suggest that, as CKD 
coding is linked to QOF incentives around 
BP targets and pharmacotherapy, 
comorbidities and risk factor management 
are likely to improve in individuals who are 
coded for CKD.
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